The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort

Little is known about the value of adding concurrent chemotherapy (CC) to radiotherapy for stage II nasopharyngeal carcinoma (NPC) with undetectable (0 copies/mL) pretreatment Epstein-Barr Virus (EBV) DNA in the intensity-modulated radiotherapy (IMRT) era. To address this question, the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ya-Nan, Tang, Qing-Nan, Yao, Ji-Jin, Xu, Xi-Wei, He, Wen-Zhuo, Wang, Lei, You, Ya-Fei, Peng, Kun-Wei, Jiang, Chang, Xia, Liang-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750417/
https://www.ncbi.nlm.nih.gov/pubmed/33338876
http://dx.doi.org/10.1016/j.tranon.2020.100990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750417/
https://www.ncbi.nlm.nih.gov/pubmed/33338876
http://dx.doi.org/10.1016/j.tranon.2020.100990

Ejemplares similares